智通财经APP讯，中国生物制药(01177)发布公告，集团附属公司正大天晴药业集团股份有限公司(正大天晴)开发的两款创新药“盐酸安罗替尼胶囊”、“TQB2916(CD40激动剂)”将在2024年美国癌症协会年会(AACR)公布5项研究成果。
临床研究：
安罗替尼：消化道肿瘤
编号：CT213/13
摘要标题：Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G001-cohort C
安罗替尼：小细胞肺癌
编号：5098/20
摘要标题：Second-line treatment outcomes in Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients after first-line immuno-chemotherapy
TQB2916：晚期恶性肿瘤
编号：CT192/20
摘要标题：A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies
基础研究：
安罗替尼：甲状腺髓样癌
编号：4665/18
摘要标题：USP18 promotes anlotinib resistance in medullary thyroid carcinoma by stabilizing aurora B kinase
安罗替尼：晚期卵巢癌
编号：3997/6
摘要标题：PARP inhibitors plus anlotinib as bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancer
